Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Questions Remain For Samsung Bioepis Post-Biogen
Management Changes, Strategic Focus And Structural Aspects Yet To Be Decided
Feb 08 2022
•
By
David Wallace
The future path for Samsung Bioepis is not yet fully decided • Source: Cagkan Sayin / Alamy Stock Photo
More from Biosimilars
More from Products